Thermo Fisher Scientific (TMO) 10-Q 1 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover	9 Months Ended
	Sep. 28, 2024 shares
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 28, 2024
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	382,500,265
Entity Central Index Key	0000097745
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	TMO
Security Exchange Name	NYSE
0.125% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Trading Symbol	TMO 25
Security Exchange Name	NYSE
3.200% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	3.200% Notes due 2026
Trading Symbol	TMO 26B
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Trading Symbol	TMO 32
Security Exchange Name	NYSE
3.650% Notes due 2034
Entity Listings [Line Items]
Title of 12(b) Security	3.650% Notes due 2034
Trading Symbol	TMO 34
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Trading Symbol	TMO 49
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,645	$ 8,077
Short-term investments	2,000	3
Accounts receivable, less allowances of $204 and $193	8,255	8,221
Inventories	5,430	5,088
Contract assets, net	1,541	1,443
Other current assets	1,911	1,757
Total current assets	23,783	24,589
Property, plant and equipment, net	9,412	9,448
Acquisition-related intangible assets, net	16,262	16,670
Other assets	4,180	3,999
Goodwill	46,726	44,020
Total assets	100,364	98,726
Current liabilities:
Short-term obligations and current maturities of long-term obligations	4,116	3,609
Accounts payable	2,606	2,872
Accrued payroll and employee benefits	1,823	1,596
Contract liabilities	2,663	2,689
Other accrued expenses	3,393	3,246
Total current liabilities	14,601	14,012
Deferred income taxes	1,123	1,922
Other long-term liabilities	4,343	4,642
Long-term obligations	31,197	31,308
Redeemable noncontrolling interest	127	118
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	0	0
Common stock, $1 par value, 1,200,000,000 shares authorized; 443,676,411 and 442,188,634 shares issued	444	442
Capital in excess of par value	17,831	17,286
Retained earnings	51,421	47,364
Treasury stock at cost, 61,176,146 and 55,541,290 shares	(18,227)	(15,133)
Accumulated other comprehensive income/(loss)	(2,477)	(3,224)
Total Thermo Fisher Scientific Inc. shareholders’ equity	48,992	46,735
Noncontrolling interests	(20)	(11)
Total equity	48,972	46,724
Total liabilities, redeemable noncontrolling interest and equity	$ 100,364	$ 98,726

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance	$ 204	$ 193
Preferred stock, $100 par value - par value (in dollars per share)	$ 100	$ 100
Preferred stock, $100 par value - shares authorized (in shares)	50,000	50,000
Preferred stock, $100 par value - shares issued (in shares)	0	0
Common stock, $1 par value - par value (in dollars per share)	$ 1	$ 1
Common stock, $1 par value - shares authorized (in shares)	1,200,000,000	1,200,000,000
Common stock, $1 par value - shares issued (in shares)	443,676,411	442,188,634
Treasury stock at cost (in shares)	61,176,146	55,541,290

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Revenues
Total revenues	$ 10,598	$ 10,574	$ 31,484	$ 31,971
Costs and operating expenses:
Selling, general and administrative expenses	2,098	2,049	6,392	6,313
Research and development expenses	346	319	1,016	1,010
Restructuring and other costs	45	84	151	379
Total costs and operating expenses	8,759	8,710	26,163	26,966
Operating income	1,838	1,864	5,321	5,005
Interest income	277	246	851	570
Interest expense	(356)	(359)	(1,073)	(985)
Other income/(expense)	(16)	14	(2)	(32)
Income before income taxes	1,742	1,765	5,096	4,558
Provision for income taxes	(99)	(53)	(507)	(151)
Equity in earnings/(losses) of unconsolidated entities	(14)	(17)	(75)	(58)
Net income	1,629	1,695	4,514	4,349
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest	0	(20)	9	(16)
Net income attributable to Thermo Fisher Scientific Inc.	$ 1,630	$ 1,715	$ 4,505	$ 4,365
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 4.26	$ 4.44	$ 11.79	$ 11.31
Diluted (in dollars per share)	$ 4.25	$ 4.42	$ 11.75	$ 11.25
Weighted average shares
Basic (in shares)	382	386	382	386
Diluted (in shares)	384	388	383	388
Product revenues
Revenues
Total revenues	$ 6,148	$ 6,157	$ 18,266	$ 18,832
Costs and operating expenses:
Cost of revenues	3,170	3,214	9,189	9,829
Service revenues
Revenues
Total revenues	4,450	4,417	13,218	13,139
Costs and operating expenses:
Cost of revenues	$ 3,100	$ 3,044	$ 9,415	$ 9,435

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Comprehensive income
Net income	$ 1,629	$ 1,695	$ 4,514	$ 4,349
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $(244), $71, $10 and $35)	(54)	(112)	748	57
Unrealized gains/(losses) on available-for-sale debt securities
Unrealized holding losses arising during the period (net of tax (provision) benefit of $0, $0, $0 and $0)	0	0	(1)	0
Unrealized gains/(losses) on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax (provision) benefit of $0, $0, $1 and $1)	1	1	2	5
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax (provision) benefit of $2, $(1), $2 and $(1))	(5)	2	(4)	2
Amortization of net loss included in net periodic pension cost (net of tax (provision) benefit of $0, $(1), $1 and $(1))	0	0	2	(2)
Total other comprehensive income/(loss)	(58)	(109)	747	62
Comprehensive income	1,572	1,586	5,261	4,411
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	6	(26)	9	(26)
Comprehensive income attributable to Thermo Fisher Scientific Inc.	$ 1,566	$ 1,612	$ 5,252	$ 4,437

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ (244)	$ 71	$ 10	$ 35
Tax (provision) benefit on unrealized holding losses arising during the period	0	0	0	0
Tax provision (benefit) on reclassification adjustment for losses included in net income	0	0	(1)	(1)
Tax benefit (provision) on pension and other postretirement benefit liability adjustments arising during the period	2	(1)	2	(1)
Tax benefit (provision) on amortization of net loss included in net periodic pension cost	$ 0	$ (1)	$ 1	$ (1)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Operating activities
Net income	$ 4,514	$ 4,349
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	852	792
Amortization of acquisition-related intangible assets	1,514	1,775
Change in deferred income taxes	(1,007)	(631)
Stock-based compensation	222	217
Other non-cash expenses, net	254	441
Changes in assets and liabilities, excluding the effects of acquisitions	(973)	(2,260)
Net cash provided by operating activities	5,377	4,683
Investing activities
Purchases of property, plant and equipment	(920)	(1,074)
Proceeds from sale of property, plant and equipment	40	76
Proceeds from cross-currency interest rate swap interest settlements	203	36
Acquisitions, net of cash acquired	(3,132)	(3,660)
Purchases of investments	(2,065)	(200)
Other investing activities, net	14	56
Net cash used in investing activities	(5,861)	(4,766)
Financing activities
Net proceeds from issuance of debt	1,204	3,466
Repayment of debt	(1,107)	(2,000)
Proceeds from issuance of commercial paper	0	1,620
Repayments of commercial paper	0	(1,935)
Purchases of company common stock	(3,000)	(3,000)
Dividends paid	(434)	(387)
Other financing activities, net	212	42
Net cash used in financing activities	(3,126)	(2,194)
Exchange rate effect on cash	182	(92)
Decrease in cash, cash equivalents and restricted cash	(3,427)	(2,369)
Cash, cash equivalents and restricted cash at beginning of period	8,097	8,537
Cash, cash equivalents and restricted cash at end of period	$ 4,670	$ 6,168

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Unaudited) - USD ($) $ in Millions	Total	Total Thermo Fisher Scientific Inc. Shareholders’ Equity	Common Stock	Capital in Excess of Par Value	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Items	Noncontrolling Interests
Beginning Balance at Dec. 31, 2022	$ 116
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	14
Other comprehensive items	(5)
Contributions from (distributions to) noncontrolling interests	(7)
Ending Balance at Sep. 30, 2023	118
Balance (in shares) at Dec. 31, 2022			441,000,000
Beginning Balance at Dec. 31, 2022	44,032	$ 43,978	$ 441	$ 16,743	$ 41,910	$ (12,017)	$ (3,099)	$ 54
Treasury stock beginning balance (in shares) at Dec. 31, 2022						50,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			1,000,000			1,000,000
Issuance of shares under stock plans	131	131	$ 1	205		$ (75)
Stock-based compensation	217	217		217
Purchases of company common stock (in shares)						5,000,000
Purchases of company common stock	(3,000)	(3,000)				$ (3,000)
Dividends declared	(406)	(406)			(406)
Net income/(loss)	4,335	4,365			4,365			(30)
Other comprehensive items	67	72					72	(5)
Contributions from (distributions to) noncontrolling interests	(1)							(1)
Excise tax from stock repurchases	(29)	(29)				$ (29)
Balance (in shares) at Sep. 30, 2023			442,000,000
Treasury stock ending balance (in shares) at Sep. 30, 2023						56,000,000
Ending Balance at Sep. 30, 2023	45,346	45,328	$ 442	17,165	45,869	$ (15,121)	(3,027)	18
Beginning Balance at Jul. 01, 2023	113
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	6
Other comprehensive items	(1)
Ending Balance at Sep. 30, 2023	118
Balance (in shares) at Jul. 01, 2023			441,000,000
Beginning Balance at Jul. 01, 2023	43,802	43,752	$ 441	17,030	44,289	$ (15,084)	(2,924)	50
Treasury stock beginning balance (in shares) at Jul. 01, 2023						55,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			1,000,000			1,000,000
Issuance of shares under stock plans	32	32	$ 1	68		$ (37)
Stock-based compensation	67	67		67
Dividends declared	(135)	(135)			(135)
Net income/(loss)	1,689	1,715			1,715			(26)
Other comprehensive items	(108)	(103)					(103)	(5)
Contributions from (distributions to) noncontrolling interests	(1)							(1)
Balance (in shares) at Sep. 30, 2023			442,000,000
Treasury stock ending balance (in shares) at Sep. 30, 2023						56,000,000
Ending Balance at Sep. 30, 2023	45,346	45,328	$ 442	17,165	45,869	$ (15,121)	(3,027)	18
Beginning Balance at Dec. 31, 2023	118
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	16
Contributions from (distributions to) noncontrolling interests	(7)
Ending Balance at Sep. 28, 2024	127
Balance (in shares) at Dec. 31, 2023			442,000,000
Beginning Balance at Dec. 31, 2023	$ 46,724	46,735	$ 442	17,286	47,364	$ (15,133)	(3,224)	(11)
Treasury stock beginning balance (in shares) at Dec. 31, 2023	55,541,290					56,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			1,000,000
Issuance of shares under stock plans	$ 259	259	$ 1	324		$ (66)
Stock-based compensation	222	222		222
Purchases of company common stock (in shares)						6,000,000
Purchases of company common stock	(3,000)	(3,000)				$ (3,000)
Dividends declared	(448)	(448)			(448)
Net income/(loss)	4,498	4,505			4,505			(7)
Other comprehensive items	747	747					747
Contributions from (distributions to) noncontrolling interests	(1)							(1)
Excise tax from stock repurchases	$ (27)	(27)				$ (27)
Balance (in shares) at Sep. 28, 2024			444,000,000
Treasury stock ending balance (in shares) at Sep. 28, 2024	61,176,146					61,000,000
Ending Balance at Sep. 28, 2024	$ 48,972	48,992	$ 444	17,831	51,421	$ (18,227)	(2,477)	(20)
Beginning Balance at Jun. 29, 2024	115
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	6
Other comprehensive items	6
Contributions from (distributions to) noncontrolling interests	0
Ending Balance at Sep. 28, 2024	127
Balance (in shares) at Jun. 29, 2024			443,000,000
Beginning Balance at Jun. 29, 2024	47,419	47,432	$ 443	17,649	49,940	$ (18,187)	(2,413)	(12)
Treasury stock beginning balance (in shares) at Jun. 29, 2024						61,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			1,000,000
Issuance of shares under stock plans	75	75	$ 1	115		$ (40)
Stock-based compensation	68	68		68
Dividends declared	(149)	(149)			(149)
Net income/(loss)	1,624	1,630			1,630			(6)
Other comprehensive items	(64)	(63)					(63)	(1)
Contributions from (distributions to) noncontrolling interests	(1)							(1)
Excise tax from stock repurchases	$ 1	1				$ 1
Balance (in shares) at Sep. 28, 2024			444,000,000
Treasury stock ending balance (in shares) at Sep. 28, 2024	61,176,146					61,000,000
Ending Balance at Sep. 28, 2024	$ 48,972	$ 48,992	$ 444	$ 17,831	$ 51,421	$ (18,227)	$ (2,477)	$ (20)

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared (in dollars per share)	$ 0.39	$ 0.35	$ 1.17	$ 1.05

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at September 28, 2024, the results of operations for the three- and nine-month periods ended September 28, 2024 and September 30, 2023, and the cash flows for the nine-month periods ended September 28, 2024 and September 30, 2023. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet presented as of December 31, 2023, has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the 2023 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Certain reclassifications of prior year amounts have been made to conform to the current year presentation. Note 1 to the consolidated financial statements for 2023 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the nine months ended September 28, 2024. Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding. Inventories The components of inventories are as follows: (In millions) September 28, 2024 December 31, 2023 Raw materials $ 1,958 $ 2,057 Work in process 902 705 Finished goods 2,570 2,326 Inventories $ 5,430 $ 5,088 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates. Recent Accounting Pronouncements The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures. Standard Description Required adoption timing and approach Impact of adoption or other significant matters Standards recently adopted ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented. Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 annual report using a prospective method Not material Standards not yet adopted ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker. 2024 annual report and interim periods thereafter using a retrospective method Will increase disclosures in Note 4 ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid. 2025 annual report and interim periods thereafter using a prospective or retrospective method Will increase disclosures in Note 5

Acquisitions

Acquisitions	9 Months Ended
	Sep. 28, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. 2024 On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation proteomics solutions. The acquisition enhances the segment’s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy opportunities. The goodwill recorded as a result of this business combination is not expected to be tax deductible. The components of the preliminary purchase price and net assets acquired are as follows: (In millions) Olink Purchase price Cash paid $ 3,215 Purchase price payable 28 Cash acquired (97) $ 3,146 Net assets acquired Definite-lived intangible assets Customer relationships $ 710 Product technology 184 Tradenames 97 Goodwill 2,263 Net tangible assets 73 Deferred tax assets (liabilities) (181) $ 3,146 The weighted-average amortization periods for definite-lived intangible assets acquired in 2024 are 19 years for customer relationships, 15 years for product technology, and 15 years for tradenames. The weighted-average amortization period for definite-lived intangible assets acquired in 2024 is 18 years. The preliminary allocation of the purchase price for the acquisition of Olink is based on the estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions. 2023 On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible. On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible. The components of the purchase price and net assets acquired are as follows: (In millions) The Binding Site CorEvitas Purchase price Cash paid $ 2,412 $ 730 Debt settled 307 184 Cash acquired (20) (4) $ 2,699 $ 910 Net assets acquired Definite-lived intangible assets: Customer relationships $ 868 $ 260 Product technology 162 47 Tradenames 42 — Backlog — 46 Goodwill 1,741 627 Net tangible assets 174 (2) Deferred tax assets (liabilities) (288) (68) $ 2,699 $ 910 In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement.

Revenues and Contract-related B

Revenues and Contract-related Balances	9 Months Ended
	Sep. 28, 2024
Revenue from Contract with Customer [Abstract]
Revenues and Contract-related Balances	Revenues and Contract-related Balances Disaggregated Revenues Revenues by type are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Revenues Consumables $ 4,379 $ 4,289 $ 13,070 $ 13,228 Instruments 1,769 1,868 5,196 5,604 Services 4,450 4,417 13,218 13,139 Consolidated revenues $ 10,598 $ 10,574 $ 31,484 $ 31,971 Revenues by geographic region based on customer location are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Revenues North America $ 5,591 $ 5,668 $ 16,640 $ 17,160 Europe 2,686 2,643 7,968 7,898 Asia-Pacific 1,923 1,913 5,755 5,801 Other regions 397 350 1,122 1,112 Consolidated revenues $ 10,598 $ 10,574 $ 31,484 $ 31,971 Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of September 28, 2024, was $25.30 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 52% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three Contract-related Balances Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows: (In millions) September 28, 2024 December 31, 2023 Current contract assets, net $ 1,541 $ 1,443 Noncurrent contract assets, net 8 4 Current contract liabilities 2,663 2,689 Noncurrent contract liabilities 1,428 1,499 In the three and nine months ended September 28, 2024, the company recognized revenues of $0.36 billion and $2.36 billion, respectively, that were included in the contract liabilities balance at December 31, 2023. In the three and nine months ended September 30, 2023, the company recognized revenues of $0.35 billion and $2.32 billion, respectively, that were included in the contract liabilities balance at December 31, 2022.

Business Segment and Geographic

Business Segment and Geographical Information	9 Months Ended
	Sep. 28, 2024
Segment Reporting [Abstract]
Business Segment and Geographical Information	Business Segment and Geographical Information Business Segment Information Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions) 2024 2023 2024 2023 Revenues Life Sciences Solutions $ 2,387 $ 2,433 $ 7,027 $ 7,508 Analytical Instruments 1,808 1,754 5,277 5,226 Specialty Diagnostics 1,129 1,083 3,355 3,300 Laboratory Products and Biopharma Services 5,740 5,728 17,221 17,322 Eliminations (467) (424) (1,397) (1,385) Consolidated revenues 10,598 10,574 31,484 31,971 Segment Income Life Sciences Solutions 845 872 2,551 2,525 Analytical Instruments 451 468 1,289 1,321 Specialty Diagnostics 293 283 886 860 Laboratory Products and Biopharma Services 773 937 2,262 2,554 Subtotal reportable segments 2,362 2,560 6,987 7,260 Cost of revenues adjustments (9) (14) (25) (73) Selling, general and administrative expenses adjustments (21) (14) 24 (28) Restructuring and other costs (45) (84) (151) (379) Amortization of acquisition-related intangible assets (450) (584) (1,514) (1,775) Consolidated operating income 1,838 1,864 5,321 5,005 Interest income 277 246 851 570 Interest expense (356) (359) (1,073) (985) Other income/(expense) (16) 14 (2) (32) Consolidated income before taxes $ 1,742 $ 1,765 $ 5,096 $ 4,558 Cost of revenues adjustments included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonment of product lines, and accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. Selling, general and administrative expenses adjustments included in the above table consist of third-party transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, charges associated with product liability litigation, and accelerated depreciation on fixed assets to be abandoned due to facility consolidations. Geographical Information Revenues by country based on customer location are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Revenues United States $ 5,406 $ 5,490 $ 16,075 $ 16,608 Other 5,192 5,084 15,409 15,363 Consolidated revenues $ 10,598 $ 10,574 $ 31,484 $ 31,971

Income Taxes

Income Taxes	9 Months Ended
	Sep. 28, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine months ended (In millions) September 28, 2024 September 30, 2023 Statutory federal income tax rate 21 % 21 % Provision for income taxes at statutory rate $ 1,070 $ 957 Increases (decreases) resulting from: Foreign rate differential (93) (176) Income tax credits (207) (217) Global intangible low-taxed income 90 66 Foreign-derived intangible income (73) (104) Excess tax benefits from stock options and restricted stock units (64) (60) Provision for (reversal of) tax reserves, net 216 9 Intra-entity transfers (102) (144) Foreign exchange loss on inter-company debt refinancing — (112) Provision for (reversal of) valuation allowances, net (161) (44) Withholding taxes 10 22 Tax return reassessments and settlements (130) (63) State income taxes, net of federal tax 50 45 Equity method investments (48) (9) Other, net (51) (19) Provision for income taxes $ 507 $ 151 During the first nine months of 2024, the company recorded a tax reserve and associated interest of $240 million related to the settlement of international tax audits for tax years 2009 through 2016, which were settled in the third quarter of 2024. The company also recorded tax benefits of $307 million, primarily in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. These benefits were partially offset by tax provisions primarily associated with disallowed interest expense that is not expected to be realized. During the third quarter of 2023, the company released a valuation allowance of $183 million in jurisdictions where the deferred tax assets are now expected to be realized. In the first nine months of 2023, the company also recorded a tax benefit of $91 million, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing transaction, as well as a $144 million tax benefit resulting from a capital loss generated as part of an intra-entity transaction. The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. Unrecognized Tax Benefits As of September 28, 2024, the company had $0.52 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2024 Balance at beginning of year $ 540 Additions for tax positions of current year 9 Additions for tax positions of prior years 220 Reductions for tax positions of prior years (46) Settlements (199) Balance at end of period $ 524

Earnings per Share

Earnings per Share	9 Months Ended
	Sep. 28, 2024
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions except per share amounts) 2024 2023 2024 2023 Net income attributable to Thermo Fisher Scientific Inc. $ 1,630 $ 1,715 $ 4,505 $ 4,365 Basic weighted average shares 382 386 382 386 Plus effect of: stock options and restricted stock units 1 2 1 2 Diluted weighted average shares 384 388 383 388 Basic earnings per share $ 4.26 $ 4.44 $ 11.79 $ 11.31 Diluted earnings per share $ 4.25 $ 4.42 $ 11.75 $ 11.25 Antidilutive stock options excluded from diluted weighted average shares 2 2 2 2

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	9 Months Ended
	Sep. 28, 2024
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements	Debt and Other Financing Arrangements Effective interest rate at September 28, September 28, December 31, (Dollars in millions) 2024 2024 2023 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) — 1,104 1.215% 3-Year Senior Notes, Due 10/18/2024 1.39 % 2,500 2,500 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 893 883 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 714 706 0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated) 1.05 % 157 158 0.00% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) 0.15 % 614 607 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 3.38 % 558 552 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 781 773 4.953% 3-Year Senior Notes, Due 8/10/2026 5.18 % 600 600 5.00% 3-Year Senior Notes, Due 12/5/2026 5.25 % 1,000 1,000 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 558 552 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 670 662 1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 1.18 % 203 205 4.80% 5-Year Senior Notes, Due 11/21/2027 5.00 % 600 600 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.77 % 893 883 1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 1.79 % 393 — 0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 0.90 % 204 206 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 670 662 1.75% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 700 5.00% 5-Year Senior Notes, Due 1/31/2029 5.24 % 1,000 1,000 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 781 773 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 1.44 % 33 33 4.977% 7-Year Senior Notes, Due 8/10/2030 5.12 % 750 750 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.89 % 1,953 1,932 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 1,005 993 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 1,200 1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 1.92 % 494 — Effective interest rate at September 28, September 28, December 31, (Dollars in millions) 2024 2024 2023 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 670 662 1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 1.60 % 44 45 4.95% 10-Year Senior Notes, Due 11/21/2032 5.09 % 600 600 5.086% 10-Year Senior Notes, Due 8/10/2033 5.20 % 1,000 1,000 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.20 % 1,674 1,656 5.20% 10-Year Senior Notes, Due 1/31/2034 5.34 % 500 500 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 3.76 % 837 828 1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 1.58 % 151 152 2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 2.10 % 387 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 781 773 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,005 993 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 1,200 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.77 % 1,395 1,380 2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 2.13 % 103 104 5.404% 20-Year Senior Notes, Due 8/10/2043 5.50 % 600 600 2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 2.06 % 204 206 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,116 1,104 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.07 % 837 828 2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 2.43 % 234 236 Other 78 77 Total borrowings at par value 35,390 35,028 Unamortized discount (104) (113) Unamortized debt issuance costs (173) (188) Total borrowings at carrying value 35,113 34,727 Finance lease liabilities 200 190 Less: Short-term obligations and current maturities 4,116 3,609 Long-term obligations $ 31,197 $ 31,308 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs. See Note 10 for fair value information pertaining to the company’s long-term borrowings. Credit Facilities The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), a Euro Interbank Offered Rate (EURIBOR)-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of September 28, 2024, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. Senior Notes Interest is payable annually on the euro and Swiss franc-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar and euro-denominated fixed rate senior notes and Japanese yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of Japanese yen-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants related to its senior notes at September 28, 2024. Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of September 28, 2024, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At September 28, 2024, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows. Litigation and Related Contingencies The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company’s 2023 financial statements and notes included in the company’s Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more such matters could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters

Comprehensive Income_(Loss) and

Comprehensive Income/(Loss) and Shareholders' Equity	9 Months Ended
	Sep. 28, 2024
Stockholders' Equity Note [Abstract]
Comprehensive Income/(Loss) and Shareholders' Equity	Comprehensive Income/(Loss) and Shareholders' Equity Comprehensive Income/(Loss) Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows: (In millions) Currency Unrealized gains/(losses) on available-for-sale debt securities Unrealized Pension and Total Three months ended September 28, 2024 Balance at June 29, 2024 $ (2,133) $ (1) $ (26) $ (253) $ (2,413) Other comprehensive income/(loss) before reclassifications (54) — — (5) (59) Amounts reclassified from accumulated other comprehensive income/(loss) (6) — 1 — (5) Net other comprehensive income/(loss) (60) — 1 (5) (63) Balance at September 28, 2024 $ (2,193) $ (1) $ (26) $ (258) $ (2,477) Nine months ended September 28, 2024 Balance at December 31, 2023 $ (2,941) $ — $ (28) $ (255) $ (3,224) Other comprehensive income/(loss) before reclassifications 749 (1) — (4) 744 Amounts reclassified from accumulated other comprehensive income/(loss) — — 2 2 4 Net other comprehensive income/(loss) 749 (1) 2 (3) 747 Balance at September 28, 2024 $ (2,193) $ (1) $ (26) $ (258) $ (2,477)

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	9 Months Ended
	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments	Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: September 28, Quoted Significant Significant (In millions) 2024 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,609 $ 1,609 $ — $ — Bank time deposits 2,000 2,000 — — Investments 45 19 — 26 Insurance contracts 239 — 239 — Derivative contracts 93 — 93 — Total assets $ 3,987 $ 3,629 $ 333 $ 26 Liabilities Derivative contracts $ 202 $ — $ 202 $ — Contingent consideration 8 — — 8 Total liabilities $ 210 $ — $ 202 $ 8 December 31, Quoted Significant Significant (In millions) 2023 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 5,021 $ 5,021 $ — $ — Bank time deposits 3 3 — — Investments 20 20 — — Insurance contracts 210 — 210 — Derivative contracts 8 — 8 — Total assets $ 5,262 $ 5,044 $ 218 $ — Liabilities Derivative contracts $ 290 $ — $ 290 $ — Contingent consideration 87 — — 87 Total liabilities $ 377 $ — $ 290 $ 87 The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair values of contingent consideration are recorded in selling, general and administrative expense. The company determines the fair value of its investments by considering factors such as financial position, operating results and cash flows of the investee; recent transactions in the same or similar securities; significant recent events affecting the investee; the price paid by Thermo Fisher; among others. In the three- and nine-month periods ended September 28, 2024, the company recorded $(4) million and $7 million, respectively, of net gains/(losses) on investments, which are included in other income/(expense) in the accompanying statements of income. In the three- and nine-month periods ended September 30, 2023, the company recorded $11 million and $(33) million, respectively, of net gains/(losses) on investments, which are included in other income/(expense) in the accompanying statements of income. The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions) 2024 2023 2024 2023 Contingent consideration Beginning balance $ 12 $ 90 $ 87 $ 174 Acquisitions (including assumed balances) — — — 1 Payments — (5) (2) (63) Changes in fair value included in earnings (4) (4) (78) (31) Ending balance $ 8 $ 81 $ 8 $ 81 The following table provides a rollforward of investments classified as level 3: Three months ended Nine months ended September 28, September 28, (In millions) 2024 2024 Investments Beginning balance $ — $ — Purchases 26 26 Ending balance $ 26 $ 26 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. (In millions) September 28, 2024 December 31, 2023 Notional amount Cross-currency interest rate swaps designated as net investment hedge - euro $ 1,000 $ 1,000 Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 4,650 4,650 Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 2,500 2,500 Currency exchange contracts 1,531 1,567 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income. Fair value – assets Fair value – liabilities September 28, December 31, September 28, December 31, (In millions) 2024 2023 2024 2023 Derivatives designated as hedging instruments Cross-currency interest rate swaps (a) $ 91 $ 5 $ 200 $ 287 Derivatives not designated as hedging instruments Currency exchange contracts (b) 2 3 2 3 Total derivatives $ 93 $ 8 $ 202 $ 290 (a) The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. Gain (loss) recognized Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions) 2024 2023 2024 2023 Derivatives designated as cash flow hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to interest expense $ (1) $ (1) $ (3) $ (6) Financial instruments designated as net investment hedges Foreign currency-denominated debt and other payables Included in currency translation adjustment within other comprehensive items (488) 364 (127) 158 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items (566) (56) 171 (6) Included in interest expense 67 35 200 68 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues (6) 2 1 (1) Included in other income/(expense) 15 (6) 5 (8) Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 to the consolidated financial statements for 2023 included in the company’s Annual Report on Form 10-K for additional information on the company’s risk management objectives and strategies. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s debt instruments are as follows: September 28, 2024 December 31, 2023 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 35,035 $ 32,959 $ 34,650 $ 32,191 Other 78 78 77 77 $ 35,113 $ 33,037 $ 34,727 $ 32,268 The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 28, 2024
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information Nine months ended (In millions) September 28, 2024 September 30, 2023 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment $ 190 $ 207 Declared but unpaid dividends 151 137 Issuance of stock upon vesting of restricted stock units 183 198 Excise tax from stock repurchases 27 29 Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: (In millions) September 28, 2024 December 31, 2023 Cash and cash equivalents $ 4,645 $ 8,077 Restricted cash included in other current assets 11 6 Restricted cash included in other assets 15 14 Cash, cash equivalents and restricted cash $ 4,670 $ 8,097 Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees, pension related deposits, and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs

Restructuring and Other Costs	9 Months Ended
	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs	Restructuring and Other Costs In the first nine months of 2024, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2024, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company’s workforce. As of November 1, 2024, the company has identified restructuring actions that it expects will result in additional charges of approximately $310 million, primarily in 2024, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. Restructuring and other costs by segment are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 28, 2024 Life Sciences Solutions $ 10 $ 26 Analytical Instruments (8) 2 Specialty Diagnostics 7 12 Laboratory Products and Biopharma Services 36 107 Corporate — 4 $ 45 $ 151 The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheet. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table. (In millions) Total (a) Balance at December 31, 2023 $ 60 Net restructuring charges incurred in 2024 (b) (c) 77 Payments (84) Balance at September 28, 2024 $ 53 (a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations. (b) Excludes $74 million of net charges, principally $54 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments. (c) Excludes $13 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $6 million attributable to a noncontrolling interest. The company expects to pay accrued restructuring costs primarily through 2024.

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 28, 2024 shares	Sep. 28, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Marc Casper [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On August 7, 2024, Marc Casper, our chairman, president and chief executive officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Casper’s plan is for the sale of up to 49,000 shares of company common stock, and the exercise of vested stock options and the associated sale of up to 71,250 shares of company common stock, through December 12, 2025. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 16, 2025.
Name	Marc Casper
Title	chairman, president and chief executive officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 7, 2024
Expiration Date	December 16, 2025
Stephen Williamson [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On August 22, 2024, Stephen Williamson, our senior vice president and chief financial officer, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Williamson’s plan is for the exercise of vested stock options and the associated sale of up to 19,650 shares of company common stock through February 26, 2026. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and February 27, 2026.
Name	Stephen Williamson
Title	senior vice president and chief financial officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 22, 2024
Expiration Date	February 27, 2026
Arrangement Duration	553 days
Aggregate Available	19,650	19,650
Frederick Lowery [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On September 9, 2024, Frederick Lowery, an executive vice president, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Lowery’s plan is for the exercise of vested stock options and the associated sale of up to 18,300 shares of company common stock through February 27, 2025, and for the gift of up to 1,304 shares of company common stock through December 13, 2024. The foregoing transactions will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold or gifted, as applicable, and February 28, 2025.
Name	Frederick Lowery
Title	executive vice president
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 9, 2024
Expiration Date	February 28, 2025
Marc Casper Trading Arrangement, Common Stock [Member] | Marc Casper [Member]
Trading Arrangements, by Individual
Arrangement Duration	492 days
Aggregate Available	49,000	49,000
Marc Casper Trading Arrangement, Vested Stock Options [Member] | Marc Casper [Member]
Trading Arrangements, by Individual
Arrangement Duration	492 days
Aggregate Available	71,250	71,250
Frederick Lowery Trading Arrangement, Vested Stock Options [Member] | Frederick Lowery [Member]
Trading Arrangements, by Individual
Arrangement Duration	171 days
Aggregate Available	18,300	18,300
Frederick Lowery Trading Arrangement, Common Stock [Member] | Frederick Lowery [Member]
Trading Arrangements, by Individual
Arrangement Duration	95 days
Aggregate Available	1,304	1,304

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures. Standard Description Required adoption timing and approach Impact of adoption or other significant matters Standards recently adopted ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented. Some aspects adopted in 2023 using a retrospective method and will adopt other aspects in 2024 annual report using a prospective method Not material Standards not yet adopted ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker. 2024 annual report and interim periods thereafter using a retrospective method Will increase disclosures in Note 4 ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid. 2025 annual report and interim periods thereafter using a prospective or retrospective method Will increase disclosures in Note 5
Acquisitions	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Components of Inventories	The components of inventories are as follows: (In millions) September 28, 2024 December 31, 2023 Raw materials $ 1,958 $ 2,057 Work in process 902 705 Finished goods 2,570 2,326 Inventories $ 5,430 $ 5,088

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 28, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Components of Purchase Price and Net Assets Acquired	The components of the preliminary purchase price and net assets acquired are as follows: (In millions) Olink Purchase price Cash paid $ 3,215 Purchase price payable 28 Cash acquired (97) $ 3,146 Net assets acquired Definite-lived intangible assets Customer relationships $ 710 Product technology 184 Tradenames 97 Goodwill 2,263 Net tangible assets 73 Deferred tax assets (liabilities) (181) $ 3,146 The components of the purchase price and net assets acquired are as follows: (In millions) The Binding Site CorEvitas Purchase price Cash paid $ 2,412 $ 730 Debt settled 307 184 Cash acquired (20) (4) $ 2,699 $ 910 Net assets acquired Definite-lived intangible assets: Customer relationships $ 868 $ 260 Product technology 162 47 Tradenames 42 — Backlog — 46 Goodwill 1,741 627 Net tangible assets 174 (2) Deferred tax assets (liabilities) (288) (68) $ 2,699 $ 910

Revenues and Contract-related_2

Revenues and Contract-related Balances (Tables)	9 Months Ended
	Sep. 28, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregated Revenues	Revenues by type are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Revenues Consumables $ 4,379 $ 4,289 $ 13,070 $ 13,228 Instruments 1,769 1,868 5,196 5,604 Services 4,450 4,417 13,218 13,139 Consolidated revenues $ 10,598 $ 10,574 $ 31,484 $ 31,971 Revenues by geographic region based on customer location are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Revenues North America $ 5,591 $ 5,668 $ 16,640 $ 17,160 Europe 2,686 2,643 7,968 7,898 Asia-Pacific 1,923 1,913 5,755 5,801 Other regions 397 350 1,122 1,112 Consolidated revenues $ 10,598 $ 10,574 $ 31,484 $ 31,971
Schedule of Contract Asset and Liability Balances	Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively. Contract asset and liability balances are as follows: (In millions) September 28, 2024 December 31, 2023 Current contract assets, net $ 1,541 $ 1,443 Noncurrent contract assets, net 8 4 Current contract liabilities 2,663 2,689 Noncurrent contract liabilities 1,428 1,499

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	9 Months Ended
	Sep. 28, 2024
Segment Reporting [Abstract]
Schedule of Business Segment Information	Business Segment Information Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions) 2024 2023 2024 2023 Revenues Life Sciences Solutions $ 2,387 $ 2,433 $ 7,027 $ 7,508 Analytical Instruments 1,808 1,754 5,277 5,226 Specialty Diagnostics 1,129 1,083 3,355 3,300 Laboratory Products and Biopharma Services 5,740 5,728 17,221 17,322 Eliminations (467) (424) (1,397) (1,385) Consolidated revenues 10,598 10,574 31,484 31,971 Segment Income Life Sciences Solutions 845 872 2,551 2,525 Analytical Instruments 451 468 1,289 1,321 Specialty Diagnostics 293 283 886 860 Laboratory Products and Biopharma Services 773 937 2,262 2,554 Subtotal reportable segments 2,362 2,560 6,987 7,260 Cost of revenues adjustments (9) (14) (25) (73) Selling, general and administrative expenses adjustments (21) (14) 24 (28) Restructuring and other costs (45) (84) (151) (379) Amortization of acquisition-related intangible assets (450) (584) (1,514) (1,775) Consolidated operating income 1,838 1,864 5,321 5,005 Interest income 277 246 851 570 Interest expense (356) (359) (1,073) (985) Other income/(expense) (16) 14 (2) (32) Consolidated income before taxes $ 1,742 $ 1,765 $ 5,096 $ 4,558
Schedule of Revenue by Country Based on Customer Location	Revenues by country based on customer location are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 30, 2023 September 28, 2024 September 30, 2023 Revenues United States $ 5,406 $ 5,490 $ 16,075 $ 16,608 Other 5,192 5,084 15,409 15,363 Consolidated revenues $ 10,598 $ 10,574 $ 31,484 $ 31,971

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 28, 2024
Income Tax Disclosure [Abstract]
Schedule of the Provision for Income Taxes	The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine months ended (In millions) September 28, 2024 September 30, 2023 Statutory federal income tax rate 21 % 21 % Provision for income taxes at statutory rate $ 1,070 $ 957 Increases (decreases) resulting from: Foreign rate differential (93) (176) Income tax credits (207) (217) Global intangible low-taxed income 90 66 Foreign-derived intangible income (73) (104) Excess tax benefits from stock options and restricted stock units (64) (60) Provision for (reversal of) tax reserves, net 216 9 Intra-entity transfers (102) (144) Foreign exchange loss on inter-company debt refinancing — (112) Provision for (reversal of) valuation allowances, net (161) (44) Withholding taxes 10 22 Tax return reassessments and settlements (130) (63) State income taxes, net of federal tax 50 45 Equity method investments (48) (9) Other, net (51) (19) Provision for income taxes $ 507 $ 151
Schedule of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2024 Balance at beginning of year $ 540 Additions for tax positions of current year 9 Additions for tax positions of prior years 220 Reductions for tax positions of prior years (46) Settlements (199) Balance at end of period $ 524

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Sep. 28, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions except per share amounts) 2024 2023 2024 2023 Net income attributable to Thermo Fisher Scientific Inc. $ 1,630 $ 1,715 $ 4,505 $ 4,365 Basic weighted average shares 382 386 382 386 Plus effect of: stock options and restricted stock units 1 2 1 2 Diluted weighted average shares 384 388 383 388 Basic earnings per share $ 4.26 $ 4.44 $ 11.79 $ 11.31 Diluted earnings per share $ 4.25 $ 4.42 $ 11.75 $ 11.25 Antidilutive stock options excluded from diluted weighted average shares 2 2 2 2

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	9 Months Ended
	Sep. 28, 2024
Debt Disclosure [Abstract]
Schedule of Outstanding Debt	Effective interest rate at September 28, September 28, December 31, (Dollars in millions) 2024 2024 2023 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) — 1,104 1.215% 3-Year Senior Notes, Due 10/18/2024 1.39 % 2,500 2,500 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 893 883 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.09 % 714 706 0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated) 1.05 % 157 158 0.00% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) 0.15 % 614 607 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 3.38 % 558 552 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 781 773 4.953% 3-Year Senior Notes, Due 8/10/2026 5.18 % 600 600 5.00% 3-Year Senior Notes, Due 12/5/2026 5.25 % 1,000 1,000 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 558 552 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 670 662 1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 1.18 % 203 205 4.80% 5-Year Senior Notes, Due 11/21/2027 5.00 % 600 600 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.77 % 893 883 1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 1.79 % 393 — 0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 0.90 % 204 206 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 670 662 1.75% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 700 5.00% 5-Year Senior Notes, Due 1/31/2029 5.24 % 1,000 1,000 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 781 773 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 1.44 % 33 33 4.977% 7-Year Senior Notes, Due 8/10/2030 5.12 % 750 750 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.89 % 1,953 1,932 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 1,005 993 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 1,200 1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 1.92 % 494 — Effective interest rate at September 28, September 28, December 31, (Dollars in millions) 2024 2024 2023 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 670 662 1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 1.60 % 44 45 4.95% 10-Year Senior Notes, Due 11/21/2032 5.09 % 600 600 5.086% 10-Year Senior Notes, Due 8/10/2033 5.20 % 1,000 1,000 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.20 % 1,674 1,656 5.20% 10-Year Senior Notes, Due 1/31/2034 5.34 % 500 500 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 3.76 % 837 828 1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 1.58 % 151 152 2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 2.10 % 387 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 781 773 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,005 993 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 1,200 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.77 % 1,395 1,380 2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 2.13 % 103 104 5.404% 20-Year Senior Notes, Due 8/10/2043 5.50 % 600 600 2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 2.06 % 204 206 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,116 1,104 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.07 % 837 828 2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 2.43 % 234 236 Other 78 77 Total borrowings at par value 35,390 35,028 Unamortized discount (104) (113) Unamortized debt issuance costs (173) (188) Total borrowings at carrying value 35,113 34,727 Finance lease liabilities 200 190 Less: Short-term obligations and current maturities 4,116 3,609 Long-term obligations $ 31,197 $ 31,308

Comprehensive Income_(Loss) a_2

Comprehensive Income/(Loss) and Shareholders' Equity (Tables)	9 Months Ended
	Sep. 28, 2024
Stockholders' Equity Note [Abstract]
Schedule of Changes in Each Component of Accumulated Other Comprehensive Items	Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows: (In millions) Currency Unrealized gains/(losses) on available-for-sale debt securities Unrealized Pension and Total Three months ended September 28, 2024 Balance at June 29, 2024 $ (2,133) $ (1) $ (26) $ (253) $ (2,413) Other comprehensive income/(loss) before reclassifications (54) — — (5) (59) Amounts reclassified from accumulated other comprehensive income/(loss) (6) — 1 — (5) Net other comprehensive income/(loss) (60) — 1 (5) (63) Balance at September 28, 2024 $ (2,193) $ (1) $ (26) $ (258) $ (2,477) Nine months ended September 28, 2024 Balance at December 31, 2023 $ (2,941) $ — $ (28) $ (255) $ (3,224) Other comprehensive income/(loss) before reclassifications 749 (1) — (4) 744 Amounts reclassified from accumulated other comprehensive income/(loss) — — 2 2 4 Net other comprehensive income/(loss) 749 (1) 2 (3) 747 Balance at September 28, 2024 $ (2,193) $ (1) $ (26) $ (258) $ (2,477)

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Schedule of Information About the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: September 28, Quoted Significant Significant (In millions) 2024 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,609 $ 1,609 $ — $ — Bank time deposits 2,000 2,000 — — Investments 45 19 — 26 Insurance contracts 239 — 239 — Derivative contracts 93 — 93 — Total assets $ 3,987 $ 3,629 $ 333 $ 26 Liabilities Derivative contracts $ 202 $ — $ 202 $ — Contingent consideration 8 — — 8 Total liabilities $ 210 $ — $ 202 $ 8 December 31, Quoted Significant Significant (In millions) 2023 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 5,021 $ 5,021 $ — $ — Bank time deposits 3 3 — — Investments 20 20 — — Insurance contracts 210 — 210 — Derivative contracts 8 — 8 — Total assets $ 5,262 $ 5,044 $ 218 $ — Liabilities Derivative contracts $ 290 $ — $ 290 $ — Contingent consideration 87 — — 87 Total liabilities $ 377 $ — $ 290 $ 87
Schedule of Fair Value of Investments	The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions) 2024 2023 2024 2023 Contingent consideration Beginning balance $ 12 $ 90 $ 87 $ 174 Acquisitions (including assumed balances) — — — 1 Payments — (5) (2) (63) Changes in fair value included in earnings (4) (4) (78) (31) Ending balance $ 8 $ 81 $ 8 $ 81 The following table provides a rollforward of investments classified as level 3: Three months ended Nine months ended September 28, September 28, (In millions) 2024 2024 Investments Beginning balance $ — $ — Purchases 26 26 Ending balance $ 26 $ 26
Schedule of the Aggregate Notional Value of Outstanding Derivative Contracts	The following table provides the aggregate notional value of outstanding derivative contracts. (In millions) September 28, 2024 December 31, 2023 Notional amount Cross-currency interest rate swaps designated as net investment hedge - euro $ 1,000 $ 1,000 Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 4,650 4,650 Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 2,500 2,500 Currency exchange contracts 1,531 1,567
Schedule of the Fair Value of Derivative Instruments	While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income. Fair value – assets Fair value – liabilities September 28, December 31, September 28, December 31, (In millions) 2024 2023 2024 2023 Derivatives designated as hedging instruments Cross-currency interest rate swaps (a) $ 91 $ 5 $ 200 $ 287 Derivatives not designated as hedging instruments Currency exchange contracts (b) 2 3 2 3 Total derivatives $ 93 $ 8 $ 202 $ 290 (a) The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
Schedule of Derivative Instruments Gains and Losses	Gain (loss) recognized Three months ended Nine months ended September 28, September 30, September 28, September 30, (In millions) 2024 2023 2024 2023 Derivatives designated as cash flow hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to interest expense $ (1) $ (1) $ (3) $ (6) Financial instruments designated as net investment hedges Foreign currency-denominated debt and other payables Included in currency translation adjustment within other comprehensive items (488) 364 (127) 158 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items (566) (56) 171 (6) Included in interest expense 67 35 200 68 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues (6) 2 1 (1) Included in other income/(expense) 15 (6) 5 (8)
Schedule of the Fair Value of the Company's Debt Instruments	The carrying value and fair value of the company’s debt instruments are as follows: September 28, 2024 December 31, 2023 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 35,035 $ 32,959 $ 34,650 $ 32,191 Other 78 78 77 77 $ 35,113 $ 33,037 $ 34,727 $ 32,268
Schedule of the Carrying Value of the Company's Debt Instruments	The carrying value and fair value of the company’s debt instruments are as follows: September 28, 2024 December 31, 2023 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 35,035 $ 32,959 $ 34,650 $ 32,191 Other 78 78 77 77 $ 35,113 $ 33,037 $ 34,727 $ 32,268

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 28, 2024
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Nine months ended (In millions) September 28, 2024 September 30, 2023 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment $ 190 $ 207 Declared but unpaid dividends 151 137 Issuance of stock upon vesting of restricted stock units 183 198 Excise tax from stock repurchases 27 29
Schedule of Cash, Cash Equivalents and Restricted Cash	Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: (In millions) September 28, 2024 December 31, 2023 Cash and cash equivalents $ 4,645 $ 8,077 Restricted cash included in other current assets 11 6 Restricted cash included in other assets 15 14 Cash, cash equivalents and restricted cash $ 4,670 $ 8,097

Restructuring and Other Costs (

Restructuring and Other Costs (Tables)	9 Months Ended
	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Costs by Segment	Restructuring and other costs by segment are as follows: Three months ended Nine months ended (In millions) September 28, 2024 September 28, 2024 Life Sciences Solutions $ 10 $ 26 Analytical Instruments (8) 2 Specialty Diagnostics 7 12 Laboratory Products and Biopharma Services 36 107 Corporate — 4 $ 45 $ 151
Schedule of Changes in the Company's Accrued Restructuring Balance	The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheet. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table. (In millions) Total (a) Balance at December 31, 2023 $ 60 Net restructuring charges incurred in 2024 (b) (c) 77 Payments (84) Balance at September 28, 2024 $ 53 (a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations. (b) Excludes $74 million of net charges, principally $54 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments. (c) Excludes $13 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $6 million attributable to a noncontrolling interest.

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,958	$ 2,057
Work in process	902	705
Finished goods	2,570	2,326
Inventories	$ 5,430	$ 5,088

Acquisitions - Components of Pu

Acquisitions - Components of Purchase Price and Net Assets Acquired (Details) - USD ($) $ in Millions	Jul. 10, 2024	Aug. 14, 2023	Jan. 03, 2023	Sep. 28, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill				$ 46,726	$ 44,020
Olink Holding AB
Business Acquisition [Line Items]
Cash paid	$ 3,215
Debt settled	28
Cash acquired	(97)
Purchase price	3,146
Goodwill	2,263
Net tangible assets	73
Deferred tax assets (liabilities)	(181)
Net assets acquired	3,146
Olink Holding AB | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets	710
Olink Holding AB | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets	184
Olink Holding AB | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets	$ 97
The Binding Site Group
Business Acquisition [Line Items]
Cash paid			$ 2,412
Debt settled			307
Cash acquired			(20)
Purchase price			2,699
Goodwill			1,741
Net tangible assets			174
Deferred tax assets (liabilities)			(288)
Net assets acquired			2,699
The Binding Site Group | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets			868
The Binding Site Group | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets			162
The Binding Site Group | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets			42
The Binding Site Group | Backlog
Business Acquisition [Line Items]
Definite-lived intangible assets			$ 0
CorEvitas, LLC
Business Acquisition [Line Items]
Cash paid		$ 730
Debt settled		184
Cash acquired		(4)
Purchase price		910
Goodwill		627
Net tangible assets		(2)
Deferred tax assets (liabilities)		(68)
Net assets acquired		910
CorEvitas, LLC | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets		260
CorEvitas, LLC | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets		47
CorEvitas, LLC | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets		0
CorEvitas, LLC | Backlog
Business Acquisition [Line Items]
Definite-lived intangible assets		$ 46

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details)	9 Months Ended	12 Months Ended
	Sep. 28, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Weighted-average amortization period		17 years
Customer relationships
Business Acquisition [Line Items]
Weighted-average amortization period	19 years	18 years
Product technology
Business Acquisition [Line Items]
Weighted-average amortization period	15 years	14 years
Tradenames
Business Acquisition [Line Items]
Weighted-average amortization period	15 years	15 years
Backlog
Business Acquisition [Line Items]
Weighted-average amortization period		13 years
Olink Holding AB
Business Acquisition [Line Items]
Weighted-average amortization period	18 years

Revenues and Contract-related_3

Revenues and Contract-related Balances - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Consolidated revenues	$ 10,598	$ 10,574	$ 31,484	$ 31,971
North America
Disaggregation of Revenue [Line Items]
Consolidated revenues	5,591	5,668	16,640	17,160
Europe
Disaggregation of Revenue [Line Items]
Consolidated revenues	2,686	2,643	7,968	7,898
Asia-Pacific
Disaggregation of Revenue [Line Items]
Consolidated revenues	1,923	1,913	5,755	5,801
Other regions
Disaggregation of Revenue [Line Items]
Consolidated revenues	397	350	1,122	1,112
Consumables
Disaggregation of Revenue [Line Items]
Consolidated revenues	4,379	4,289	13,070	13,228
Instruments
Disaggregation of Revenue [Line Items]
Consolidated revenues	1,769	1,868	5,196	5,604
Services
Disaggregation of Revenue [Line Items]
Consolidated revenues	$ 4,450	$ 4,417	$ 13,218	$ 13,139

Revenues and Contract-related_4

Revenues and Contract-related Balances - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation amount	$ 25,300		$ 25,300
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 360	$ 350	$ 2,360	$ 2,320
Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Warranty agreement (in years)	3 years		3 years
Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Warranty agreement (in years)	5 years		5 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-09-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation percentage	52%		52%
Remaining performance obligation, expected timing	12 months		12 months

Revenues and Contract-related_5

Revenues and Contract-related Balances - Schedule of Contract Asset and Liability Balances (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Current contract assets, net	$ 1,541	$ 1,443
Noncurrent contract assets, net	8	4
Current contract liabilities	2,663	2,689
Noncurrent contract liabilities	$ 1,428	$ 1,499

Business Segment and Geograph_3

Business Segment and Geographical Information - Schedule of Business Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Consolidated revenues	$ 10,598	$ 10,574	$ 31,484	$ 31,971
Segment Income	1,838	1,864	5,321	5,005
Restructuring and other costs	(45)	(84)	(151)	(379)
Amortization of acquisition-related intangible assets			(1,514)	(1,775)
Interest income	277	246	851	570
Interest expense	(356)	(359)	(1,073)	(985)
Other income/(expense)	(16)	14	(2)	(32)
Consolidated income before taxes	1,742	1,765	5,096	4,558
Total Reportable Segments
Segment Reporting Information [Line Items]
Segment Income	2,362	2,560	6,987	7,260
Total Reportable Segments | Life Sciences Solutions
Segment Reporting Information [Line Items]
Consolidated revenues	2,387	2,433	7,027	7,508
Segment Income	845	872	2,551	2,525
Restructuring and other costs	(10)		(26)
Total Reportable Segments | Analytical Instruments
Segment Reporting Information [Line Items]
Consolidated revenues	1,808	1,754	5,277	5,226
Segment Income	451	468	1,289	1,321
Restructuring and other costs	8		(2)
Total Reportable Segments | Specialty Diagnostics
Segment Reporting Information [Line Items]
Consolidated revenues	1,129	1,083	3,355	3,300
Segment Income	293	283	886	860
Restructuring and other costs	(7)		(12)
Total Reportable Segments | Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Consolidated revenues	5,740	5,728	17,221	17,322
Segment Income	773	937	2,262	2,554
Restructuring and other costs	(36)		(107)
Eliminations
Segment Reporting Information [Line Items]
Consolidated revenues	(467)	(424)	(1,397)	(1,385)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Cost of revenues adjustments	(9)	(14)	(25)	(73)
Selling, general and administrative expenses adjustments	(21)	(14)	24	(28)
Restructuring and other costs	(45)	(84)	(151)	(379)
Amortization of acquisition-related intangible assets	$ (450)	$ (584)	$ (1,514)	$ (1,775)

Business Segment and Geograph_4

Business Segment and Geographical Information - Schedule of Revenue by Country Based on Customer Location (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated revenues	$ 10,598	$ 10,574	$ 31,484	$ 31,971
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated revenues	5,406	5,490	16,075	16,608
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated revenues	$ 5,192	$ 5,084	$ 15,409	$ 15,363

Income Taxes - Schedule of the

Income Taxes - Schedule of the Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory federal income tax rate			21%	21%
Provision for income taxes at statutory rate			$ 1,070	$ 957
Foreign rate differential			(93)	(176)
Income tax credits			(207)	(217)
Global intangible low-taxed income			90	66
Foreign-derived intangible income			(73)	(104)
Excess tax benefits from stock options and restricted stock units			(64)	(60)
Provision for (reversal of) tax reserves, net			216	9
Intra-entity transfers			(102)	(144)
Foreign exchange loss on inter-company debt refinancing			0	(112)
Provision for (reversal of) valuation allowances, net		$ (183)	(161)	(44)
Withholding taxes			10	22
Tax return reassessments and settlements			(130)	(63)
State income taxes, net of federal tax			50	45
Equity method investments			(48)	(9)
Other, net			(51)	(19)
Provision for income taxes	$ 99	$ 53	$ 507	$ 151

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 28, 2024 USD ($) country	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Valuation Allowance [Line Items]
Provision for (reversal of) tax reserves, net		$ 216	$ 9
Provision for (reversal of) valuation allowances, net	$ (183)	(161)	(44)
Tax benefit from foreign exchange loss on an intercompany debt refinancing transaction			91
Intra-entity transfers		$ (102)	$ (144)
Countries with taxable presence | country		70
Unrecognized tax benefits		$ 524		$ 540
Foreign Tax Jurisdiction
Valuation Allowance [Line Items]
Provision for (reversal of) tax reserves, net		240
Provision for (reversal of) valuation allowances, net		$ (307)

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) $ in Millions	9 Months Ended
	Sep. 28, 2024 USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 540
Additions for tax positions of current year	9
Additions for tax positions of prior years	220
Reductions for tax positions of prior years	(46)
Settlements	(199)
Balance at end of period	$ 524

Earnings per Share - Schedule o

Earnings per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net income attributable to Thermo Fisher Scientific Inc.	$ 1,630	$ 1,715	$ 4,505	$ 4,365
Basic weighted average shares (in shares)	382	386	382	386
Plus effect of: stock options and restricted stock units (in shares)	1	2	1	2
Diluted weighted average shares (in shares)	384	388	383	388
Basic earnings per share (in dollars per share)	$ 4.26	$ 4.44	$ 11.79	$ 11.31
Diluted earnings per share (in dollars per share)	$ 4.25	$ 4.42	$ 11.75	$ 11.25
Antidilutive stock options excluded from diluted weighted average shares (in shares)	2	2	2	2

Debt and Other Financing Arra_3

Debt and Other Financing Arrangements - Schedule of Outstanding Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total borrowings at par value	$ 35,390	$ 35,028
Unamortized discount	(104)	(113)
Unamortized debt issuance costs	(173)	(188)
Total borrowings at carrying value	35,113	34,727
Finance lease liabilities	200	190
Less: Short-term obligations and current maturities	4,116	3,609
Long-term obligations	31,197	31,308
Senior Notes
Debt Instrument [Line Items]
Total borrowings at carrying value	$ 35,035	34,650
Senior Notes | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.75%
Term	8 years
Total borrowings at par value		1,104
Senior Notes | 1.215% 3-Year Senior Notes, Due 10/18/2024
Debt Instrument [Line Items]
Interest rate	1.215%
Term	3 years
Effective interest rate	1.39%
Total borrowings at par value	$ 2,500	2,500
Senior Notes | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.125%
Term	5 years 6 months
Effective interest rate	0.41%
Total borrowings at par value	$ 893	883
Senior Notes | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2%
Term	10 years
Effective interest rate	2.09%
Total borrowings at par value	$ 714	706
Senior Notes | 0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	0.853%
Term	3 years
Effective interest rate	1.05%
Total borrowings at par value	$ 157	158
Senior Notes | 0.00% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0%
Term	4 years
Effective interest rate	0.15%
Total borrowings at par value	$ 614	607
Senior Notes | 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	3.20%
Term	3 years
Effective interest rate	3.38%
Total borrowings at par value	$ 558	552
Senior Notes | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.40%
Term	8 years 6 months
Effective interest rate	1.53%
Total borrowings at par value	$ 781	773
Senior Notes | 4.953% 3-Year Senior Notes, Due 8/10/2026
Debt Instrument [Line Items]
Interest rate	4.953%
Term	3 years
Effective interest rate	5.18%
Total borrowings at par value	$ 600	600
Senior Notes | 5.00% 3-Year Senior Notes, Due 12/5/2026
Debt Instrument [Line Items]
Interest rate	5%
Term	3 years
Effective interest rate	5.25%
Total borrowings at par value	$ 1,000	1,000
Senior Notes | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.45%
Term	10 years
Effective interest rate	1.65%
Total borrowings at par value	$ 558	552
Senior Notes | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.75%
Term	7 years
Effective interest rate	1.97%
Total borrowings at par value	$ 670	662
Senior Notes | 1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.054%
Term	5 years
Effective interest rate	1.18%
Total borrowings at par value	$ 203	205
Senior Notes | 4.80% 5-Year Senior Notes, Due 11/21/2027
Debt Instrument [Line Items]
Interest rate	4.80%
Term	5 years
Effective interest rate	5%
Total borrowings at par value	$ 600	600
Senior Notes | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.50%
Term	8 years 6 months
Effective interest rate	0.77%
Total borrowings at par value	$ 893	883
Senior Notes | 1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.6525%
Term	4 years
Effective interest rate	1.79%
Total borrowings at par value	$ 393	0
Senior Notes | 0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	0.77%
Term	5 years
Effective interest rate	0.90%
Total borrowings at par value	$ 204	206
Senior Notes | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.375%
Term	12 years
Effective interest rate	1.46%
Total borrowings at par value	$ 670	662
Senior Notes | 1.75% 7-Year Senior Notes, Due 10/15/2028
Debt Instrument [Line Items]
Interest rate	1.75%
Term	7 years
Effective interest rate	1.89%
Total borrowings at par value	$ 700	700
Senior Notes | 5.00% 5-Year Senior Notes, Due 1/31/2029
Debt Instrument [Line Items]
Interest rate	5%
Term	5 years
Effective interest rate	5.24%
Total borrowings at par value	$ 1,000	1,000
Senior Notes | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.95%
Term	12 years
Effective interest rate	2.08%
Total borrowings at par value	$ 781	773
Senior Notes | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Interest rate	2.60%
Term	10 years
Effective interest rate	2.74%
Total borrowings at par value	$ 900	900
Senior Notes | 1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.279%
Term	7 years
Effective interest rate	1.44%
Total borrowings at par value	$ 33	33
Senior Notes | 4.977% 7-Year Senior Notes, Due 8/10/2030
Debt Instrument [Line Items]
Interest rate	4.977%
Term	7 years
Effective interest rate	5.12%
Total borrowings at par value	$ 750	750
Senior Notes | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.80%
Term	9 years
Effective interest rate	0.89%
Total borrowings at par value	$ 1,953	1,932
Senior Notes | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.875%
Term	12 years
Effective interest rate	1.13%
Total borrowings at par value	$ 1,005	993
Senior Notes | 2.00% 10-Year Senior Notes, Due 10/15/2031
Debt Instrument [Line Items]
Interest rate	2%
Term	10 years
Effective interest rate	2.23%
Total borrowings at par value	$ 1,200	1,200
Senior Notes | 1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.8401%
Term	8 years
Effective interest rate	1.92%
Total borrowings at par value	$ 494	0
Senior Notes | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.375%
Term	12 years
Effective interest rate	2.55%
Total borrowings at par value	$ 670	662
Senior Notes | 1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.49%
Term	10 years
Effective interest rate	1.60%
Total borrowings at par value	$ 44	45
Senior Notes | 4.95% 10-Year Senior Notes, Due 11/21/2032
Debt Instrument [Line Items]
Interest rate	4.95%
Term	10 years
Effective interest rate	5.09%
Total borrowings at par value	$ 600	600
Senior Notes | 5.086% 10-Year Senior Notes, Due 8/10/2033
Debt Instrument [Line Items]
Interest rate	5.086%
Term	10 years
Effective interest rate	5.20%
Total borrowings at par value	$ 1,000	1,000
Senior Notes | 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.125%
Term	12 years
Effective interest rate	1.20%
Total borrowings at par value	$ 1,674	1,656
Senior Notes | 5.20% 10-Year Senior Notes, Due 1/31/2034
Debt Instrument [Line Items]
Interest rate	5.20%
Term	10 years
Effective interest rate	5.34%
Total borrowings at par value	$ 500	500
Senior Notes | 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	3.65%
Term	12 years
Effective interest rate	3.76%
Total borrowings at par value	$ 837	828
Senior Notes | 1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.50%
Term	12 years
Effective interest rate	1.58%
Total borrowings at par value	$ 151	152
Senior Notes | 2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	2.0375%
Term	12 years
Effective interest rate	2.10%
Total borrowings at par value	$ 387	0
Senior Notes | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.875%
Term	20 years
Effective interest rate	2.94%
Total borrowings at par value	$ 781	773
Senior Notes | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.50%
Term	20 years
Effective interest rate	1.73%
Total borrowings at par value	$ 1,005	993
Senior Notes | 2.80% 20-Year Senior Notes, Due 10/15/2041
Debt Instrument [Line Items]
Interest rate	2.80%
Term	20 years
Effective interest rate	2.90%
Total borrowings at par value	$ 1,200	1,200
Senior Notes | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.625%
Term	20 years
Effective interest rate	1.77%
Total borrowings at par value	$ 1,395	1,380
Senior Notes | 2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.069%
Term	20 years
Effective interest rate	2.13%
Total borrowings at par value	$ 103	104
Senior Notes | 5.404% 20-Year Senior Notes, Due 8/10/2043
Debt Instrument [Line Items]
Interest rate	5.404%
Term	20 years
Effective interest rate	5.50%
Total borrowings at par value	$ 600	600
Senior Notes | 2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.02%
Term	20 years
Effective interest rate	2.06%
Total borrowings at par value	$ 204	206
Senior Notes | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Interest rate	5.30%
Term	30 years
Effective interest rate	5.37%
Total borrowings at par value	$ 400	400
Senior Notes | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Interest rate	4.10%
Term	30 years
Effective interest rate	4.23%
Total borrowings at par value	$ 750	750
Senior Notes | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.875%
Term	30 years
Effective interest rate	1.98%
Total borrowings at par value	$ 1,116	1,104
Senior Notes | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2%
Term	30 years
Effective interest rate	2.07%
Total borrowings at par value	$ 837	828
Senior Notes | 2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.382%
Term	30 years
Effective interest rate	2.43%
Total borrowings at par value	$ 234	236
Other
Debt Instrument [Line Items]
Total borrowings at par value	78	77
Total borrowings at carrying value	$ 78	$ 77

Debt and Other Financing Arra_4

Debt and Other Financing Arrangements (Details)	9 Months Ended
	Sep. 28, 2024 USD ($)
Senior Notes
Short-term Financing [Line Items]
Redemption price (as a percent)	100%
0.00% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	0%
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	0.80%
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	1.125%
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	1.625%
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) | Senior Notes
Short-term Financing [Line Items]
Interest rate	2%
Commercial Paper | U.S. Commercial Paper Program
Short-term Financing [Line Items]
Maximum maturity period	397 days
Commercial Paper | Euro Commercial Paper Program
Short-term Financing [Line Items]
Maximum maturity period	183 days
Revolving Credit Facility
Short-term Financing [Line Items]
Borrowing capacity	$ 5,000,000,000
Minimum consolidated interest coverage ratio	3.5
Borrowings outstanding	$ 0

Comprehensive Income_(Loss) a_3

Comprehensive Income/(Loss) and Shareholders' Equity - Schedule of Changes in Each Component of Accumulated Other Comprehensive Items (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 28, 2024	Sep. 28, 2024
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 47,419	$ 46,724
Ending Balance	48,972	48,972
Currency translation adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(2,133)	(2,941)
Other comprehensive income/(loss) before reclassifications	(54)	749
Amounts reclassified from accumulated other comprehensive income/(loss)	(6)	0
Net other comprehensive income/(loss)	(60)	749
Ending Balance	(2,193)	(2,193)
Unrealized gains/(losses) on available-for-sale debt securities
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(1)	0
Other comprehensive income/(loss) before reclassifications	0	(1)
Amounts reclassified from accumulated other comprehensive income/(loss)	0	0
Net other comprehensive income/(loss)	0	(1)
Ending Balance	(1)	(1)
Unrealized gains/(losses) on hedging instruments
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(26)	(28)
Other comprehensive income/(loss) before reclassifications	0	0
Amounts reclassified from accumulated other comprehensive income/(loss)	1	2
Net other comprehensive income/(loss)	1	2
Ending Balance	(26)	(26)
Pension and other postretirement benefit liability adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(253)	(255)
Other comprehensive income/(loss) before reclassifications	(5)	(4)
Amounts reclassified from accumulated other comprehensive income/(loss)	0	2
Net other comprehensive income/(loss)	(5)	(3)
Ending Balance	(258)	(258)
Total
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(2,413)	(3,224)
Other comprehensive income/(loss) before reclassifications	(59)	744
Amounts reclassified from accumulated other comprehensive income/(loss)	(5)	4
Net other comprehensive income/(loss)	(63)	747
Ending Balance	$ (2,477)	$ (2,477)

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments - Assets and Liabilities on a Recurring Basis (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 31, 2023
Liabilities
Gain (loss) on sale of investments	$ (4)	$ 11	$ 7	$ (33)
Fair Value, Recurring
Assets
Cash equivalents	1,609		1,609		$ 5,021
Bank time deposits	2,000		2,000		3
Investments	45		45		20
Insurance contracts	239		239		210
Derivative contracts	93		93		8
Total assets	3,987		3,987		5,262
Liabilities
Derivative contracts	202		202		290
Contingent consideration	8		8		87
Total liabilities	210		210		377
Fair Value, Recurring | Quoted Prices in Active Markets (Level 1)
Assets
Cash equivalents	1,609		1,609		5,021
Bank time deposits	2,000		2,000		3
Investments	19		19		20
Insurance contracts	0		0		0
Derivative contracts	0		0		0
Total assets	3,629		3,629		5,044
Liabilities
Derivative contracts	0		0		0
Contingent consideration	0		0		0
Total liabilities	0		0		0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)
Assets
Cash equivalents	0		0		0
Bank time deposits	0		0		0
Investments	0		0		0
Insurance contracts	239		239		210
Derivative contracts	93		93		8
Total assets	333		333		218
Liabilities
Derivative contracts	202		202		290
Contingent consideration	0		0		0
Total liabilities	202		202		290
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)
Assets
Cash equivalents	0		0		0
Bank time deposits	0		0		0
Investments	26		26		0
Insurance contracts	0		0		0
Derivative contracts	0		0		0
Total assets	26		26		0
Liabilities
Derivative contracts	0		0		0
Contingent consideration	8		8		87
Total liabilities	$ 8		$ 8		$ 87

Fair Value Measurements and F_4

Fair Value Measurements and Fair Value of Financial Instruments - Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Investments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Purchases	$ 26		$ 26
Ending balance	26		26
Contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	12	$ 90	87	$ 174
Acquisitions (including assumed balances)	0	0	0	1
Payments	0	(5)	(2)	(63)
Changes in fair value included in earnings	(4)	(4)	(78)	(31)
Ending balance	$ 8	$ 81	$ 8	$ 81
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible Enumeration]			Selling, general and administrative expenses	Selling, general and administrative expenses

Fair Value Measurements and F_5

Fair Value Measurements and Fair Value of Financial Instruments - Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 31, 2023
Fair Value, Recurring
Derivatives, Fair Value [Line Items]
Fair value – assets	$ 93	$ 8
Fair value – liabilities	202	290
Interest rate swaps | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - euro
Derivatives, Fair Value [Line Items]
Notional amount	1,000	1,000
Interest rate swaps | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - Japanese yen
Derivatives, Fair Value [Line Items]
Notional amount	4,650	4,650
Interest rate swaps | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - Swiss franc
Derivatives, Fair Value [Line Items]
Notional amount	2,500	2,500
Cross-currency interest rate swaps | Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Fair value – assets	91	5
Fair value – liabilities	200	287
Currency exchange contracts
Derivatives, Fair Value [Line Items]
Notional amount	1,531	1,567
Currency exchange contracts | Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Fair value – assets	2	3
Fair value – liabilities	$ 2	$ 3

Fair Value Measurements and F_6

Fair Value Measurements and Fair Value of Financial Instruments - Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Currency exchange contracts | Included in cost of product revenues | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	$ (6)	$ 2	$ 1	$ (1)
Currency exchange contracts | Included in other income/(expense) | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	15	(6)	5	(8)
Derivatives designated as cash flow hedges | Interest rate swaps | Amount reclassified from accumulated other comprehensive items to interest expense | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on cash flow hedge reclassified from AOCI	(1)	(1)	(3)	(6)
Financial instruments designated as net investment hedges | Foreign currency-denominated debt and other payables | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on currency translation adjustment	(488)	364	(127)	158
Financial instruments designated as net investment hedges | Cross-currency interest rate swaps | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on currency translation adjustment	(566)	(56)	171	(6)
Gain (loss) on derivative	$ 67	$ 35	$ 200	$ 68

Fair Value Measurements and F_7

Fair Value Measurements and Fair Value of Financial Instruments - Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	$ 35,113	$ 34,727
Fair value	33,037	32,268
Senior notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	35,035	34,650
Fair value	32,959	32,191
Other
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	78	77
Fair value	$ 78	$ 77

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Non-cash Investing and Financing Activities [Abstract]
Acquired but unpaid property, plant and equipment	$ 190	$ 207
Declared but unpaid dividends	151	137
Issuance of stock upon vesting of restricted stock units	183	198
Excise tax from stock repurchases	27	29
Cash and cash equivalents	4,645		$ 8,077
Restricted cash included in other current assets	11		6
Restricted cash included in other assets	15		14
Cash, cash equivalents and restricted cash	$ 4,670	$ 6,168	$ 8,097	$ 8,537
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets		Other current assets
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration]	Other assets		Other assets

Restructuring and Other Costs -

Restructuring and Other Costs - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Nov. 01, 2024
Restructuring Cost and Reserve [Line Items]
Workforce reduction	2%
Subsequent Event
Restructuring Cost and Reserve [Line Items]
Additional restructuring charges		$ 310

Restructuring and Other Costs_2

Restructuring and Other Costs - Schedule of Restructuring and Other Costs by Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	$ 45	$ 84	$ 151	$ 379
Corporate, Non-Segment
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs			4
Life Sciences Solutions | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	10		26
Analytical Instruments | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	(8)		2
Specialty Diagnostics | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	7		12
Laboratory Products and Biopharma Services | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	$ 36		$ 107

Restructuring and Other Costs_3

Restructuring and Other Costs - Reserves (Details) $ in Millions	9 Months Ended
	Sep. 28, 2024 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 60
Net restructuring charges incurred in 2024	77
Payments	(84)
Ending balance	53
Non-cash charges	74
Impairment of long-lived assets	54
Impairment of disposal group	13
Attributable to noncontrolling interest	$ 6